These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 10873024

  • 1. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.
    Alavi K, Schwartz MZ, Palazzo JP, Prasad R.
    J Pediatr Surg; 2000 Jun; 35(6):847-51. PubMed ID: 10873024
    [Abstract] [Full Text] [Related]

  • 2. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease.
    Peterson RL, Wang L, Albert L, Keith JC, Dorner AJ.
    Lab Invest; 1998 Dec; 78(12):1503-12. PubMed ID: 9881950
    [Abstract] [Full Text] [Related]

  • 3. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease.
    Thatch KA, Mendelson KG, Haber MM, Schwartz MZ.
    J Surg Res; 2009 Oct; 156(2):245-9. PubMed ID: 19524260
    [Abstract] [Full Text] [Related]

  • 4. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
    Bertrand V, Quéré S, Guimbaud R, Sogni P, Chauvelot-Moachon L, Tulliez M, Lamarque D, Charreire J, Giroud JP, Couturier D, Chaussade S, Breban M.
    Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
    [Abstract] [Full Text] [Related]

  • 5. Measurement of cytokine mRNA expression in intestinal biopsies of cats with inflammatory enteropathy using quantitative real-time RT-PCR.
    Nguyen Van N, Taglinger K, Helps CR, Tasker S, Gruffydd-Jones TJ, Day MJ.
    Vet Immunol Immunopathol; 2006 Oct 15; 113(3-4):404-14. PubMed ID: 16879876
    [Abstract] [Full Text] [Related]

  • 6. GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.
    Prasad R, Alavi K, Schwartz MZ.
    J Pediatr Surg; 2001 Apr 15; 36(4):570-2. PubMed ID: 11283879
    [Abstract] [Full Text] [Related]

  • 7. Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.
    Bowen-Yacyshyn MB, Bennett CF, Nation N, Rayner D, Yacyshyn BR.
    J Pharmacol Exp Ther; 2002 Sep 15; 302(3):908-17. PubMed ID: 12183646
    [Abstract] [Full Text] [Related]

  • 8. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.
    Martin GR, Wallace LE, Sigalet DL.
    Am J Physiol Gastrointest Liver Physiol; 2004 Jun 15; 286(6):G964-72. PubMed ID: 14962847
    [Abstract] [Full Text] [Related]

  • 9. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease.
    Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R.
    J Pediatr Surg; 2004 Mar 15; 39(3):448-52; discussion 448-52. PubMed ID: 15017568
    [Abstract] [Full Text] [Related]

  • 10. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
    Dubé PE, Forse CL, Bahrami J, Brubaker PL.
    Gastroenterology; 2006 Aug 15; 131(2):589-605. PubMed ID: 16890611
    [Abstract] [Full Text] [Related]

  • 11. Up-regulated intragraft gene expression, ICAM-1 and IL-2R molecules, and apoptotic epithelial cells during rejection of rat small intestine allografts.
    Li Y, Li N, Li Y, Wu B, Li J.
    Chin Med J (Engl); 2001 Oct 15; 114(10):1089-94. PubMed ID: 11677773
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2.
    Ivory CP, Wallace LE, McCafferty DM, Sigalet DL.
    Am J Physiol Gastrointest Liver Physiol; 2008 Dec 15; 295(6):G1202-10. PubMed ID: 18845573
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
    Bulut K, Meier JJ, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, Schmidt WE, Gallwitz B.
    Regul Pept; 2004 Sep 15; 121(1-3):137-43. PubMed ID: 15256284
    [Abstract] [Full Text] [Related]

  • 14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Jan 15; 424():1-304. PubMed ID: 12616287
    [Abstract] [Full Text] [Related]

  • 15. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
    Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y.
    J Autoimmun; 2007 Jan 15; 29(2-3):187-94. PubMed ID: 17804196
    [Abstract] [Full Text] [Related]

  • 16. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
    Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, Poulsen SS.
    Gut; 2004 Aug 15; 53(8):1145-50. PubMed ID: 15247183
    [Abstract] [Full Text] [Related]

  • 17. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I, Hasan F, Khan I.
    Scand J Gastroenterol; 2009 Aug 15; 44(1):56-64. PubMed ID: 18785066
    [Abstract] [Full Text] [Related]

  • 18. Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease.
    Peterson RL, Wang L, Albert L, Marchese E, Erickson J, Wong A, Mounts WM, Hayes L, Bouchard P, Keith J, Dorner AJ.
    Pharmacogenomics J; 2002 Aug 15; 2(6):383-99. PubMed ID: 12629504
    [Abstract] [Full Text] [Related]

  • 19. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression.
    Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE.
    J Immunol; 1993 May 01; 150(9):4168-78. PubMed ID: 8473755
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
    L'Heureux MC, Brubaker PL.
    J Pharmacol Exp Ther; 2003 Jul 01; 306(1):347-54. PubMed ID: 12815012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.